Safety and activity of IMAB362 in combination with zoledronic acid and interleukin-2 in CLDN18.2-positive Gastric Cancer

Trial Identifier: GM-IMAB-001-04
Sponsor: Astellas Pharma Global Development, Inc.
Start Date: October 2012
Primary Completion Date: October 2014
Study Completion Date: October 2014

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Germany Freiburg, Germany, 79106
Germany Leipzig, Germany, 04109
Germany Tübingen, Germany, 72076
Germany Ulm, Germany, 89070
Germany, Berlin Berlin, Germany, 13353
Germany, Hessen Frankfurt, Hessen, Germany, 60488
Germany, Sachsen Dresden, Sachsen, Germany, 01307
Latvia Liepaja, Latvia, 3401
Latvia Riga, Latvia, LV1038